Price$49.86+1.04 (+2.13%)
01:30 PM07:45 PM
News · 26 weeks65+100%
2026-03-012026-08-23
Mix2090d
- Insider9(45%)
- SEC Filings4(20%)
- Analyst3(15%)
- Earnings3(15%)
- Other1(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by SVP, Global Controller and CAO Woodworth Emily4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by EVP and CFO Monson Jonathan4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- PRBoston Scientific announces participation in Wells Fargo 21st Annual Healthcare Conference and conference call discussing third quarter 2026 resultsMARLBOROUGH, Mass., Aug. 10, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will participate in Wells Fargo's 21st Annual Healthcare Conference on Thursday, September 10, 2026. Mike Mahoney, chairman and chief executive officer, and Kenneth Stein, M.D., senior vice president and global chief medical officer, will participate in a 35-minute question-and-answer session with the host analyst at approximately 8:00 a.m. ET. Additionally, the company will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2026, on Wednesday, October 28, 2026, at 8:
- INSIDERDirector Habiger David C bought $99,937 worth of shares (2,100 units at $47.59), increasing direct ownership by 14% to 17,160 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Boston Scientific CorporationSCHEDULE 13G/A - BOSTON SCIENTIFIC CORP (0000885725) (Subject)
- INSIDERDirector Habiger David C bought $56,887 worth of shares (1,182 units at $48.13), increasing direct ownership by 9% to 15,060 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERChairman, President & CEO Mahoney Michael F bought $9,001,408 worth of shares (186,240 units at $48.33), increasing direct ownership by 13% to 1,590,024 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERSEC Form 4 filed by EVP & Group Pres, Cardiology Fitzgerald Joseph Michael4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Ludwig Edward J bought $227,400 worth of shares (5,000 units at $45.48), increasing direct ownership by 20% to 30,359 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECSEC Form 10-Q filed by Boston Scientific Corporation10-Q - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- ANALYSTBoston Scientific downgraded by ArgusArgus downgraded Boston Scientific from Buy to Hold
- PRPenumbra, Inc. Reports Second Quarter 2026 Financial ResultsALAMEDA, Calif., July 30, 2026 /PRNewswire/ -- Penumbra, Inc. (NYSE:PEN), the world's leading thrombectomy company, today reported financial results for the second quarter ended June 30, 2026. Revenue of $390.0 million in the second quarter of 2026, an increase of 14.9% compared to the second quarter of 2025.Global thrombectomy revenue of $259.0 million in the second quarter of 2026, an increase of 12.5% compared to the second quarter of 2025.Global embolization and access revenue of $131.1 million in the second quarter of 2026, an increase of 20.0% compared to the second quarter of 2025.Gross profit margin of 67.9% in the seco
- SECBoston Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRBoston Scientific announces results for second quarter 2026MARLBOROUGH, Mass., July 29, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) generated net sales of $5.442 billion during the second quarter of 2026, growing 7.5 percent on a reported basis and 7.0 percent on an operational1 and organic2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $907 million or $0.61 per share (EPS), compared to $797 million or $0.53 per share a year ago, and achieved adjusted3 EPS of $0.86 for the period, compared to $0.75 a year ago. "Our team delivered a solid quarter while continuing to navigate a
- SECBoston Scientific Corporation filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities8-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- INSIDEREVP and CFO Monson Jonathan covered exercise/tax liability with 1,010 shares and converted options into 2,087 shares, increasing direct ownership by 3% to 39,063 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECSEC Form 11-K filed by Boston Scientific Corporation11-K - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- INSIDERChairman, President & CEO Mahoney Michael F gifted 386,755 shares (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- ANALYSTBoston Scientific downgraded by Wolfe ResearchWolfe Research downgraded Boston Scientific from Outperform to Peer Perform
- ANALYSTBoston Scientific downgraded by Wells Fargo with a new price targetWells Fargo downgraded Boston Scientific from Overweight to Equal Weight and set a new price target of $55.00
- INSIDERDirector Ludwig Edward J bought $202,914 worth of shares (3,580 units at $56.68), increasing direct ownership by 16% to 25,359 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Pegus Cheryl bought $99,987 worth of shares (1,770 units at $56.49) (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- INSIDERDirector Habiger David C bought $251,098 worth of shares (4,450 units at $56.43), increasing direct ownership by 47% to 13,878 units (SEC Form 4)4 - BOSTON SCIENTIFIC CORP (0000885725) (Issuer)
- SECSEC Form SD filed by Boston Scientific CorporationSD - BOSTON SCIENTIFIC CORP (0000885725) (Filer)
- PRFRACTURE IDE trial of the Boston Scientific SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter meets primary safety and effectiveness endpointsLate-breaking data from global pivotal study achieved high rates of freedom from major adverse cardiac events and procedural success in patients with severe coronary artery diseaseMARLBOROUGH, Mass. and PARIS, May 19, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) today announced positive results from the pivotal FRACTURE Investigational Device Exemption (IDE) trial evaluating the use of the SEISMIQ™ 4CE Coronary Intravascular Lithotripsy Catheter* to treat patients with severely calcified coronary artery disease (CAD). The study met its primary safety and effectiveness endpoints, demonstrating high rates of freedom from major adverse cardiac events (MACE) at 30 days as well a
BSX FAQ
6 questionsWhat does Boston Scientific Corporation do?
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also...Where does BSX stock trade?
Boston Scientific Corporation (BSX) is listed on NYSE.What sector and industry is BSX in?
Boston Scientific Corporation operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about BSX?
Boston Scientific Corporation has had 8 recent analyst actions on file. The most recent action was from Argus: Hold on 2026-07-31.What companies are similar to BSX?
Notable peers in the same industry include JNJ (Johnson & Johnson), ABT (Abbott Laboratories), SYK (Stryker Corporation), MDT (Medtronic plc.), BDX (Becton Dickinson and Company). Compare BSX side-by-side with any of them on Quantisnow.How can I track BSX on Quantisnow?
Quantisnow aggregates Boston Scientific Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BSX to receive live email and push alerts on every new disclosure.